

CURRICULUM VITAE

Dara L. Aisner, M.D., Ph.D.

Personal Information

Address:

[REDACTED]
Aurora, Co 80045

Contact Information

[REDACTED]
[REDACTED] (office)
[REDACTED] (fax)
[REDACTED] (cell)

Current Position:

Vice Chair for Genomic Laboratory Medicine, Department of Pathology, University of Colorado School of Medicine
Professor, Department of Pathology, University of Colorado School of Medicine
Director, Colorado Molecular Correlates Laboratory, Department of Pathology
Section Director, Molecular Pathology Section of Pathology Shared Resource, University of Colorado Cancer Center

Education & Training:

8/1992 - 6/1996 B.S., *magna cum laude*, Molecular Biology with honors; Vanderbilt University, Nashville, Tennessee

5/1996 - 6/2004 M.D.; University of Texas Southwestern Medical School
Dallas, Texas

5/1996 - 6/2004 Ph.D.; University of Texas Southwestern Graduate School
Dallas, Texas

7/2007 - 6/2008 Resident/Clinical Fellow, Anatomic Pathology; National Institutes
& 7/2004 - 9/2006 of Health
Bethesda, Maryland

7/2008 - 6/2009 Fellow, Surgical Pathology, Department of Pathology and Laboratory
Medicine, University of Pennsylvania Hospital
Philadelphia, Pennsylvania

7/2009 – 6/2010 Fellow, Molecular and Genetic Pathology, Department of Pathology and
Laboratory Medicine, University of Pennsylvania Hospital
Philadelphia, Pennsylvania

Academic Appointments:

8 / 2010 – 6 / 2016 Assistant Professor, University of Colorado School of Medicine
7 / 2016 – 6/2021 Associate Professor, University of Colorado School of Medicine
7/2022 – present Professor, University of Colorado School of Medicine

Hospital, Government or other Professional Positions:

9/2006 – 7/2007 Program Officer, Roundtable on Evidence-Based Medicine
 Institute of Medicine, Washington, DC

2/2015 – 2018 Co-Director, Molecular Tumor Board
 University of Colorado Health

Honors, Special Recognitions and Awards:

Phi Beta Kappa; Vanderbilt University; March 1996

Magna cum laude; Vanderbilt University; June 1996

Merck Scholars Training Grant, University of Texas Southwestern Medical School
Medical Scientist Training Program

H.T. Enterline Surgical Pathology Fellowship Award; University of Pennsylvania; June 2009

REACH Resident Research Award Grant, 2009-2010
Project Title: MicroRNA Expression in H.pylori associated Gastric Carcinogenesis

CAP Foundation Research Grant, 2009-2010; Project Title: Identification and Validation of
Gene Targets for CpG Promoter Methylation for Risk Stratification in GIST

President's Award for World Class Clinical Care, 2012; University of Colorado Hospital

Summit Award for Teaching Excellence, Department of Pathology;
University of Colorado, 2019

Summit Award for Teaching Excellence, Department of Pathology;
University of Colorado, 2020

Representative in receipt of 'Pathologist of the Year' Award, co-awarded to the Colorado Molecular Correlates Laboratory, 2021

Summit Award for Teaching Excellence, Department of Pathology;
University of Colorado, 2021

Professional Society Membership:

2014- 2017	American Society of Clinical Pathology (ASCP) Section Director, Molecular Pathology, ASCP Education Working Group
2012 - 2014	American Society of Clinical Oncology
2009 - present	Association for Molecular Pathology Junior Member, Training and Education Task Force (2010-2011) Junior Member, Economic Affairs Committee (2013- 2014) Full Member, Economic Affairs Committee (2015 – 2018) Member, Task Force on Resident Curriculum in Molecular Pathology (2011-present)
2009 - present	International Association for the Study of Lung Cancer Member, Local Organizing Committee, World Conference on Lung Cancer
2004 - 2018	United States and Canadian Academy of Pathology
2009 - present	College of American Pathologists

Major Committee and Service Responsibilities:

Departmental:

Vice Chair for Genomic Laboratory Medicine, 2022-present

Director, Colorado Molecular Correlates Laboratory, 2015-present

Colorado Molecular Correlates Laboratory Executive Committee, 2010- 2015

Attending Pathologist, Surgical Pathology (Pulmonary focus), 2010 – present

Attending Pathologist, Molecular Pathology, 2010 - present

University of Colorado Department of Pathology:

Search Committee for Faculty Member in Hematopathology, 2012

University of Colorado Department of Pathology:

Search Committee for Faculty Member in Head and Neck Pathology, 2011-2014

University of Colorado Comprehensive Cancer Center:

Search Committee for Associate Director of Clinical Services, 2011-2012

University of Colorado Department of Pathology, Grand Rounds Committee;
Member (2013-2014)

University of Colorado Department of Pathology:

Interviewer for Histology Supervisor position (2018)

University of Colorado Department of Pathology:

Interviewer for multiple faculty positions (e.g. GI pathology, dermatopathology, Highlands Ranch Hospital pathologist, breast pathology, GYN pathology), 2018

University of Colorado Department of Pathology:

Laboratory Information System (LIS) Search Committee for CMOCO/CGL, 2019-present

University of Colorado Department of Pathology:

Participated in 3 promotion committees, one as committee chair, 2020

University of Colorado Department of Pathology:

Associate Program Director, Molecular Genetic Pathology Fellowship, 2020-present

University of Colorado Department of Pathology:

Advisory Committee for formation of a fellowship in Bone and Soft Tissue Pathology, 2020

Institutional:

Associate Member, University of Colorado Cancer Center, 2010 – 2017

Full Member, University of Colorado Cancer Center, 2017-present

University of Colorado Comprehensive Cancer Center:

Ad Hoc reviewer for Lung Cancer SPORE program, 2011 – present

University of Colorado Anschutz Medical Center and CU Foundation:

Medical Center Outreach Tours, 2011-present

Co-Director, Molecular Pathology Shared Resource, 2013 - 2020

University of Colorado School of Medicine External Speakers Conflict of Interest Committee,
2013- present

University of Colorado Cancer Center:

ORIEN Molecular RFQ Task Force, Member, 2015-2017

Internal Advisory Board, Biostatistics and Bioinformatics Shared Resource, 2016-current

University of Colorado Cancer Center:

Thoracic Oncology Research Initiative Leader search committee, 2016-2017

Admissions Committee, Medical Scientist Training Program (MSTP), 2018-2020

University of Colorado School of Medicine:

Search Committee for Chair, Department of Biochemistry and Molecular Genetics, 2018-2019

University of Colorado Cancer Center:

Thoracic Oncology Research Initiative Leader search committee (replacement position), 2020-TBD

Member, UCHHealth Clinical Laboratory COVID-19 Working Group

Lead pathologist for 3D printed nasopharyngeal swab acquisition

Lead pathologist for pre-analytic/extraction automation for MDX

Lead pathologist for pooling optimization based on HHS questionnaire

Ad-hoc participation in daily COVID-19 laboratory briefings, as necessary

University of Colorado/University of Colorado Health:

Working group to develop a supply-chain independent serology assay for SARS-CoV-2, 2020

University of Colorado School of Medicine:

Review Committee for a proposed new division within the Department of Anesthesiology, 2020

Leadership Committee, Pathology Shared Resource, 2020-present

(previously Molecular Pathology Shared Resource)

Molecular Pathology Special Representative, University of Colorado Cancer Center Executive Committee, 2021-present

Member, Data Sharing Working Group, CRIO Council, 2022-present

Chair, Biomarkers Resource Committee, 2022-2023

Member, Expert Panel, cfDNA testing in solid tumors and lymphoma, American Society of Clinical Oncology, 2022-present

Association of Molecular Pathology liaison to American Society of Clinical Oncology Guidelines Strategy Committee, 2022-present

Professional Society:

Clinical Laboratory Standards Institute:

Contributor, Document Development Committee on Molecular Diagnostic Methods for Nonhematological Cancers, 2011-present

Association for Molecular Pathology:

Member, Training and Education Committee, 2010-2011

Association for Molecular Pathology:

Member, Task Force on Resident Curriculum in Molecular Pathology, 2011-2016

Association for Molecular Pathology:

Member, Economic Affairs Committee, 2013- 2018

American Society for Clinical Pathology:

Annual Meeting Steering Committee, Molecular Section Director, 2013-2016

Lung Cancer Mutation Consortium, Genomics Subcommittee, 2013-2018

Local Organizing Committee, World Conference on Lung Cancer to be held in Denver, 2015, 2014-2015

American Society of Cytopathology/Papanicolaou Society joint task force on recommendations for utilization of cytopathology specimens for molecular testing, March 2014-2015

Association for Molecular Pathology:

Member, Taskforce on Proposed FDA Regulation of Next Generation Sequencing: October 2014-present

American Medical Association:

Member, Taskforce on Proposed FDA Regulation of Laboratory Developed Tests; January 2015-present

Association for Molecular Pathology:

Member, Expert Panel: Molecular Testing Guideline for the Selection of Lung Cancer Patients –Revision (Collaborative Guidelines from IASLC/CAP/AMP), January 2015- 2018

College of American Pathologists: Genomic Medicine Committee, March 2018- present

Association for Molecular Pathology:

Expert Advisor: Guidelines for Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies (Collaborative Guidelines from CAP/AMP/ATS, others), 2018

Local Organizing Committee, World Conference on Lung Cancer to be held in Denver, 2021, 2020-present

Pathology and Biomarkers Track Chair, World Conference on Lung Cancer to be held in Denver, 2021, 2020-present

Co-Founder and Co-Lead, Genomics Organization for Academic Laboratories, 2017-present (organization formally incorporated in 2020).

Chair, Board of Managers, Genomics Organization for Academic Laboratories, 2020-present

Member, CAP/AMP Joint Working Group on Tapestry Pilot Project, 2020 - present

Other:

Genomics Committee, Lung Cancer Mutation Consortium I, 2011-2015

Genomics Committee, Lung Cancer Mutation Consortium II, 2015 – 2020

Member, Non-Small Cell Lung Cancer Panel, National Comprehensive Cancer Network (NCCN), 2016 – present

Co-Lead, Lung Cancer Somatic Working Group, ClinGen, 2017- 2020

Informal advisor to NPR Science Desk Reporter Richard Harris on matters related to Pathology and Laboratory Medicine, 2019- current

<https://www.npr.org/sections/health-shots/2019/12/23/787403509/for-her-head-cold-insurer-coughed-up-25-865>

Expert Advisory Committee Member:

Association of Community Cancer Centers Committee for Creating Operational Pathways to Integrate Molecular Testing in Lung Cancer into Community Cancer Centers, 2020-present

Licensure:

Colorado-Unrestricted

Maryland - Unrestricted (Inactive)

Board Certification:

Anatomic Pathology (June, 2008)

Molecular Genetic Pathology (September, 2011)

Clinical Informatics (October, 2016)

Review and Referee Work:Editorial Boards:

Diagnostic Cytopathology, Section Editor, Molecular Pathology, 2013 – 2015

Diagnostic Cytopathology, Associate Editor, 2015-2017

Archives of Pathology and Laboratory Medicine, Section Editor, Precision Medicine, 2015 – present

JCO Precision Oncology – Editorial Board, 2016-present

Grant Reviewer

Cancer Research UK

Medical Research Council UK

Invited Ad Hoc Reviewer (Journals):

Acta Cytologica

Archives of Pathology and Laboratory Medicine

Cancer

Cancer Cytopathology

Cancer Genetics

Clinical Cancer Research

Cancer Research

Diagnostic Cytopathology

Drug Discovery Today

Experimental Lung Research

Histopathology

International Journal of Cancer

JAMA Oncology

Journal of Clinical Pathology

Journal of Molecular Diagnostics

Journal of Molecular Diagnosis and Therapy

Journal of Thoracic Oncology

JCO Precision Oncology

Lung Cancer

Modern Pathology

Molecular Cancer and Therapy

The Oncologist

Virchows Archiv

Invited Ad Hoc Reviewer (Meeting Abstracts):

World Conference on Lung Cancer, 2015

World Conference on Lung Cancer, 2020

Invited Extramural Lectures, Presentations and Visiting Professorships:

Local:

“Molecular Testing”

Pfizer Lung Cancer Preceptorship. Hosted by the University of Colorado Cancer Center Lung Program, March, 2011

“Pathology 101”

Bladder Cancer Advocacy Network, September, 2011

“Molecular Pathology and EGFR Mutation Testing”

Boehringer Ingelheim Learning Experience Preceptorship, Hosted by the University of Colorado Cancer Center Lung Program, March, 2012

“Innovations in Molecular Pathology: Improving Patient Care and Accelerating Translational Research”

Pathology Grand Round, University of Colorado, April, 2014

“Next Generation Sequencing: From Research Tool to Clinical Reality”

Endocrine Department Research Conference, December, 2014

“Clinical and Translational Next Generation Sequencing: The Road Ahead”

Developmental Therapeutics and Molecular Oncology Joint Retreat, March, 2015

“Solid Tumor Molecular Testing: Opportunities, Implications and Outlook”

Presentation to local genetic counselors monthly meeting, April, 2015

“Molecular Testing in NSCLC”

Clovis Oncology Learning Experience Preceptorship, Hosted by the University of Colorado Cancer Center Lung Program, April, 2015

“Next Generation Sequencing: Optimizing Detection of Clinically Actionable Alterations”,

Pathology Grand Rounds, University of Colorado, January, 2016

“FISH Testing in Lung Carcinoma”

Colorado Genetics Laboratory, June, 2017

“A Potpourri of Updates in Molecular Pathology”

Department of Pathology Grand Rounds, University of Colorado, April, 2018

“Pathology Update”

University of Colorado Thoracic Oncology Retreat, March, 2019

“Standing up the AMC SARS-CoV-2 Serologic Test: A Collaborative and Evolving (Ad)venture”

CU Innovations SPARK lecture series, June, 2020 (web-based remote presentation)

“Pre-Analytic Variables in Anatomic Pathology”

lecture to first year residents during ‘boot camp’ July, 2021

“Molecular Testing: Somatic Testing at CMOCO and Elsewhere”, presentation to system-wide cancer Genetic Counselors, December, 2021

Regional:

“Molecular Diagnostic Applications in Anatomic Pathology”

Pennsylvania Association of Pathologists Annual Meeting, April, 2010, Harrisburgh, PA

“Non-Small Cell Lung Cancer: From Morphology to Molecular Classification”

Memorial Hospital Colorado Springs, February, 2014

“Molecular Profiling: What You Need to Know”

Rose Hospital Tumor Board Invited Presentation, July, 2014

“Non-Small Cell Lung Cancer: Morphology and Molecular Testing”

Poudre Valley Hospital, July, 2014

“Molecular Testing and Next Generation Sequencing: What You Need to Know”

Rocky Mountain Oncology Society, September, 2014

“Update on Pathology and Molecular Testing of GI Cancers”

UC System-Wide GI Retreat, December, 2014

“Molecular Pathology”

UC System-Wide Lung Retreat, April, 2015, Fort Collins, CO

“Managing Small Specimens for Molecular Studies: Tips, Tools and Techniques”

Colorado Society of Histopathologists, May, 2015, Denver, CO

“Ripped Genes: Women Fighting Lung Cancer”

Keynote Speaker: Lung Force Walk, Taking a Breath for Women Breakfast, Sponsored by the American Lung Association, December, 2015, Denver, CO

“Update on Pathology and Molecular Testing of GI Malignancies”
UC System-Wide GI Retreat, December, 2016

“Ripped Genes: Women Fighting Lung Cancer”
American Lung Association Board of Directors Meeting, January, 2016, Denver, CO

“Molecular Profiling: Oncogenes and immunotherapy: just what is ‘routine’ anymore?”
OncLive State of the Science Symposium, August, 2018

“Update on Molecular Pathology”
System-wide GI Malignancies Retreat, August, 2021

“Update on Molecular Pathology for the Practicing Oncologist”
Rocky Mountain Oncology Society, August, 2021

“Scoring the GOAL: A Multi-Institutional Collaborative Effort to Accelerate Advancement and Implementation of Academic Genomic Diagnostics in Oncology”
Grand Rounds, Department of Pathology, University of Colorado, September, 2021

National:

“Lessons Learned from Molecular Analysis of ‘Unbelievably Small’
Cytology Specimens”
United States and Canadian Academy of Pathology Annual Meeting, San Antonio, TX,
February, 2011

“What is Molecular Pathology”
Webinar for Global Resource for Advancing Cancer Education, August, 2012

“Molecular Testing for Predictive Markers: Advances and Insights into ALK Therapy
Resistance”
University of Pennsylvania Department of Pathology Grand Rounds, November, 2012,
Philadelphia, PA

“Challenges and Opportunities in Patient-Centered Lung Cancer Care: Where are we now and
Where are we going?”
Expert panel discussion presented by PeerViewPress, January 2015 (no longer available
online)

“Validation and Implementation of Next Generation Sequencing Based Solid Tumor Profiling”

Corporate Session Day of the Association for Molecular Pathology Annual Meeting,
November, 2013, Phoenix, AZ

“Managing Small Specimens for Molecular Studies: Tips, Tools and Techniques”
Memorial Sloan Kettering Cancer Center Department of Pathology, November, 2013,
New York, NY

“Current and Emerging Markers in Non-Small Cell Lung Cancer: Applications in
Cytopathology”
Papanicolaou Society Annual Meeting, March, 2014, San Diego, CA

“Managing Small Specimens for Molecular and Ancillary Studies: Tips, Tools and Techniques”
Practice Changers, USCAP Annual Meeting, March, 2014, San Diego, CA

“Tissue is the Issue: The Pathologist’s Role in Facilitating Molecular Diagnostics”
American Society of Clinical Oncology Annual Meeting, June, 2014, Chicago, IL

“Validation of TruSight Tumor Panel Next Generation Sequencing Assay in FFPE Specimens”
LUNG SPORE annual meeting, July, 2014, Rockville, MD

“Molecular Testing: Specimens, Systems and Standardization”
Invited talk to employees of Clovis Oncology, September, 2014, San Francisco, CA

“You want me to send what to where? What the Pathologist needs to know in selecting material
for molecular studies”
American Society of Clinical Pathology Annual Meeting, October, 2014, Tampa, FL

“Tips, Tools and Tricks for Managing Small Specimens for Molecular Testing”
New York University Department of Pathology Grand Rounds, November, 2014,
New York, NY

“Managing Small Specimens for Molecular Studies: Tips, Tools and Techniques”
University of Minnesota Department of Pathology Grand Rounds, March, 2015

“Molecular Characterization of Non-Small Cell Lung Cancer”
American Thoracic Society Annual Meeting, May 2015, Denver, CO

“Regulation of Laboratory Developed Tests: How Did we Get Here, Where are We Now, and
Where are We Going?”
CGC-CAGdb (Cancer Genomics Consortium/Cytogenomics Array Group CNV database) 6th
Summer Meeting, August, 2015, Denver, CO

“You want me to send what to where? What the Pathologist needs to know in selecting material for molecular studies”

American Society of Clinical Pathology Annual Meeting, November, 2015, Long Beach, CA

“Regulation of Laboratory Developed Tests: Potential Impact on Molecular Cytopathology (& Other Ancillary Testing)”

Educational Session at the Annual Meeting of the American Society of Cytopathology, November, 2015, Chicago, IL

“Confronting and Mitigating Pre-Analytic Variability”

The United States Food and Drug Administration Workshop on Next-Generation Sequencing based Oncology Panels’. February, 2016, White Oak, MD

“Hot Topics in Molecular Pathology”

USCAP Annual Meeting, March, 2016, Seattle, WA

“Update on Molecular Testing of Cytopathology Samples”

Papanicolaou Society Annual Meeting, March, 2016, Seattle, WA

“Expanded Genomic Testing in Lung Adenocarcinoma Expands the Survival Benefit”

American Society of Clinical Oncology Annual Meeting, June, 2016, Chicago, IL

“Regulatory & Reimbursement Elements of Next Generation Sequencing (NGS):

Balancing Quality and Innovation”

SPECSII, July, 2017, via Webex to Albuquerque, NM

“The Evolving Landscape of Molecular Testing in Lung Cancer: Who, How and When”

Global Resource for Advancing Cancer Education, August, 2017, Denver, CO

“Use of Tissue for Molecular Testing”

Albert Institute Symposium on Bladder Cancer, September, 2016, Denver, CO

“Regulatory and Reimbursement Elements of Molecular Testing”

Houston Biomarkers Symposium, September, 2016, Houston, TX

“Molecular Diagnostics & Next Generation Sequencing (NGS): Increasing Application in Regulatory Clinical Trials & Routine Practice”

Oncology Master Class, Biomedical Learning Institute, October, 2016, Dallas, TX

“Practical Guide to Selecting Tissue for Molecular Diagnostics: A Case-based Approach and Live Microscope Tutorial”

American Society of Clinical Pathology Annual Meeting, October, 2016, Las Vegas, NV

“Approach to Molecular Testing in NSCLC”

American Society of Cytopathology companion meeting to American Society of Clinical Pathology Annual Meeting, October, 2016, Las Vegas, NV

“Confronting and Mitigating Variability”

Precision Medicine World Congress, January, 2017, Palo Alto, CA

“Testing in Lung Cancer”

Lung Cancer Master Class, Biomedical Learning Institute, February, 2017, Dallas, TX

“Optimal Specimen Collection for Biomarker Testing in Lung Cancer”

College of American Pathologists Webinar, October, 2017

“NSCLC Pathology and Molecular Testing – What Should Clinicians Know?”

International Association for the Study of Lung Cancer Webinar, October, 2017

“Pathology and Related Critical Issues Facing Immune Therapy”

Immunotherapy Master Class, Biomedical Learning Institute, November, 2017, Dallas, TX

“Molecular Testing to Enable Neoadjuvant Trials in NSCLC”

United States Food and Drug Administration, March, 2018, Bethesda, MD (presented remotely)

“Role of Pathologic Features in the Management of Lung Cancer”

American Society of Clinical Oncology Annual Meeting Educational Symposium, June, 2018, Chicago, IL

“Best Practices for Small Specimen Management in NSCLC”

Association for Molecular Pathology Live Webcast, August, 2018

“Molecular Testing: Regulatory and Reimbursement Considerations”

Cancer Biomarkers Conference, September, 2018, Houston, TX

“EGFR Mutation Testing: Operational Considerations”

Evening Symposium at the College of American Pathologists Annual Meeting, October, 2018, Chicago, IL

“Assessing RET-Altered Tumors: An Increasingly Important Target for Personalized Oncology Care”

Evening Symposium at the College of American Pathologists Annual Meeting, October, 2018, Chicago, IL

“Emerging Targets for the Diagnosis of Cancer: NTRK Fusions in Solid Tumors”

Evening Symposium at the Association for Molecular Pathology Annual Meeting, November, 2018, San Antonio, TX

“Strength in Numbers: Building an Academic Consortium to Facilitate Cost-Effective Clinical NGS”

Association for Molecular Pathology Annual Meeting, November, 2018, San Antonio, TX

“Maximizing Resources: Lessons Learned at the Macro and Micro Scale”

Yale University, September, 2019, New Haven, CT

“Biomarker Testing in Non-Small Cell Lung Cancer”

National Comprehensive Cancer Network (NCCN) Lung Cancer Congress, November, 2019, Baltimore, MD

“Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and Updated Guidelines: What Pathologists Need to Know and Do”

California Society of Pathologists Annual Meeting, December, 2019, San Francisco, CA

“Omics Driven Oncology: Academic Center Implementation”

United States Food and Drug Administration Oncology Center of Excellence Series ‘Omics-Driven Oncology: A Primer for FDA Staff; February, 2020 (web-based remote presentation to audience in Rockville, Maryland)

“RET as a Diagnostic and Therapeutic Target in NSCLC and Thyroid Cancer”

USCAP Annual Meeting, February, 2020, Los Angeles, CA

“Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage and Reimbursement”

webinar companion to the Journal of Molecular Diagnostics article (see Bibliography)(held virtually) July, 2021

Session Moderator, National Lung Cancer Roundtable Biomarkers Summit, Breakout Group on Reimbursement, Cost and Coverage of Biomarker Testing, September, 2020 (meeting held virtually)

“A Multi-Institutional Collaborative Effort to Facilitate Development and Standardization of Clinical Research Next Generation Sequencing”

Advances in Genome Biology and Technology Precision Health Summit, 2020 (web-based remote presentation)

“Next Generation Sequencing: Nuts and Bolts”

Next Generation Sequencing Short Course, Association for Molecular Pathology Annual Meeting, November, 2020 (web-based remote presentation for a virtual meeting, originally scheduled for Vancouver BC in-person presentation)

“Scoring the GOAL: The Genomics Organization for Academic Laboratories”

Association for Molecular Pathology Annual Meeting Corporate Workshops, November, 2020 (web-based remote presentation for a virtual meeting, originally scheduled for Vancouver BC in-person presentation)

“Update on Molecular Pathology”

California Society of Pathologists Annual Meeting, December, 2020 (web-based remote presentation for a virtual meeting, originally scheduled for San Francisco in-person presentation)

“Oncology Molecular Testing in the Era of COVID-19”

Invited speaker for Brigham and Women’s Hospital Surgical Pathology Lecture Series, January, 2021 (web-based remote presentation)

“Non-Small Cell Lung Cancer: Biomarker Testing Recommendations”

National Comprehensive Cancer Network (NCCN) Annual Cancer Congress, March, 2021 (virtual conference)

“Precision Decisions in Genomic Testing and Targeted Treatment of NSCLC”

Companion CME meeting at USCAP 2021 (virtual session), March, 2021

“Moving Mountains: (R)Evolution of LDT Regulation in the Face of COVID-19”

Invited Presentation to the CLIA Advisory Committee (CLIAC), Centers for Disease Control (CDC), April, 2021 (held virtually)

“Advances in the Treatment of Metastatic Colorectal Cancer”

National Comprehensive Cancer Network (NCCN) Colorectal Cancer Tumor Board Series, May, 2021 (virtual session)

“The ABCs of Genomic Variants: Unweaving the Complex Web of Molecular Data to Improve Patient Care”

Invited speaker for Educational Session at the American Society of Clinical Oncology 2021 Annual Meeting, virtual meeting, June, 2021

“Genomic Testing in Oncology: Finding and Filling the Holes”

Invited speaker for Genomeweb educational session, July 2021 (virtual webinar)

“The Importance of Biomarker Testing in Oncology”, Invited speaker for the NCCN Employer Forum (virtual), October, 2021

“General Principles of Test Interpretations: What Results are Actionable and How to Advise Patients About Results?” at the NCCN 2021 Biomarkers Congress (virtual), November, 2021

“Molecular Markers for Targeted Lung Cancer Therapy and Immunotherapy Response” Invited speaker for AMP Companion Society Course at United States and Canadian Academy of Pathology Annual Meeting, Los Angeles, CA, March, 2022

“Scoring the GOAL: A Multi-Institutional Collaborative Effort to Accelerate Advancement and Implementation of Academic Genomic Diagnostics in Oncology” for the Hoosier Cancer Network (virtual), April, 2022

“Uncovering Oncogenic Markers in Advanced NSCLC: Update on Testing Technologies” Invited speaker for Continuing Education Symposium at ASCO Annual Meeting, Chicago, IL, June, 2022

“Best Practices for Molecular Testing in Advanced NSCLC and Decoding NGS Reports” Invited speaker for Medscape, virtual program, February, 2023

“The Case of the Missing ALK”, Invited speaker for the Binaytara Foundation Symposium, San Diego, CA, February 2023

“Collaboration Across Specialties”, Invited speaker for trainee focused session at Targeted Therapies in Lung Cancer, Santa Monica, CA, February, 2023

“How We Do It: Integrating Gene Fusion Testing in Oncology Clinics for Patients with NSCLC”, Invited speaker for Continuing Education Symposium at ASCO Annual Meeting, Chicago, IL, June 2023

“The Genomics Organization for Academic Laboratories (GOAL): A Model for Cooperation in Pathology and Laboratory Medicine, Invited speaker at the Association for Diagnostic Laboratory Medicine Annual Conference, July, 2023

International:

“Molecular Cytopathology: Specimen Type and Preparation and Oncogene Mutational Testing on Cytology Specimens: An Evolving Practice”
3rd Annual International Molecular Cytopathology Meeting, September, 2012, Naples, Italy

“Regulatory Elements of Next Generation Sequencing: Balancing Quality and Innovation”
Workshop Presentation, International Association for the Study of Lung Cancer, September, 2015, Denver, CO

“Testing for T790M in Tissue and in Blood”
Education Session Presentation, International Association for the Study of Lung Cancer, September, 2015, Denver, CO

“PRO: Laboratory Developed Tests for Immuno-Oncology”

Invited presentation, World Conference on Lung Cancer, September, 2018, Toronto, Canada

“Reflex Testing of Advanced NSCLC: The Benefits and Barriers”

Invited presentation for educational session, World Conference on Lung Cancer, January, 2021 (web-based remote presentation for a virtual meeting, originally scheduled for Singapore in August 2020)

“Expect the Unexpected: Molecular Pathology Elucidation of Challenging Anatomic Pathology Cases”, Canadian Anatomic and Molecular Pathology Education Series, CAMP PODS 2023 (Hosted in Vancouver, BC)

Teaching Activities:

Course Director, resident rotation in molecular pathology at the Colorado Molecular Correlates Laboratory, December 2010-Present

Small Group Leader, Medical Student Pathology Course, 2010 - present (1-3 sessions/year)

Lecturer, Hematology-Oncology Fellows Didactic Series, February 2011-2014 (1-3 lectures/year)

Lecturer, Pathology Resident Didactic Series, June 2011-Present (2-5 lectures/year)

Lecturer, Physician Assistant Didactic Series Pathology Course, October 2011-2018 (1-2 lectures/year)

Lecturer, Clinical Sciences Graduate Course, 2012

Lecturer, Dental School Core Curriculum, 2013-2018 (2-4 lectures/year)

Lecturer, 4th year Medical School Elective Course “Interpretation of Clinical Laboratory Tests” 2014-current (1 lecture/year)

Director, Medical Student Preceptorship in Molecular Pathology, 2016-current

Core Faculty, Molecular Genetic Pathology Fellowship Program

Lecturer, Pathology Resident ‘Boot Camp’ Orientation Program for 1st year residents

Grants and Contracts:

Shared Resource Co-Director, Cancer Center Support Grant, National Cancer Institute, \$176,000 (PI: Schulick)

5P30CA046934-33
9/1/2018-8/31/2023
0.6 calendar

Investigator, Assay Validation of Targeted RNA sequencing to Detect Kinase Gene Fusions, National Cancer Institute/Subcontract with The Ohio State University (PI: Roychowdhury)
4UH3CA202971-02
9/2018-9/2019
0.6 calendar

Investigator, A Phase II study of ponatanib in cohorts of patients with lung cancer preselected using different candidate biomarkers, National Cancer Institute, \$1,484,023 (PI: Camidge)
Funded Privately (ARIAD Pharmaceuticals)
10/2013-10-2018
0.47 calendar

Co-Investigator, Southwest Early Trials Consortium, National Cancer Institute, \$639,707 (PI: Messersmith)
UNM1CA186685
7/2014-5/2018
0.6 calendar

Co-Investigator, Feasibility study for large-scale, population-based validation of a molecular staging tool for bladder cancer, University of Colorado Cancer Center Pilot Grant, \$50,000, direct costs only
11/2011-10/2013

Bibliography:

Peer-reviewed original articles:

1. Holt SE, **Aisner DL**, Shay JW, Wright WE: Lack of cell cycle regulation of telomerase activity in human cells. *Proc Natl Acad Sci U S A* 1997, 94:10687-92. PMID: 9380696
2. Holt SE, **Aisner DL**, Baur J, Tesmer VM, Dy M, Ouellette M, Trager JB, Morin GB, Toft DO, Shay JW, Wright WE, White MA: Functional requirement of p23 and Hsp90 in telomerase complexes. *Genes Dev* 1999, 13:817-26. PMID: 10197982
3. Ouellette MM, **Aisner DL**, Savre-Train I, Wright WE, Shay JW: Telomerase activity does not always imply telomere maintenance. *Biochem Biophys Res Commun* 1999, 254:795-803. PMID: 9920820
4. Tesmer VM, Ford LP, Holt SE, Frank BC, Yi X, **Aisner DL**, Ouellette M, Shay JW, Wright WE: Two inactive fragments of the integral RNA cooperate to assemble active telomerase with the human protein catalytic subunit (hTERT) in vitro. *Mol Cell Biol* 1999, 19:6207-16. PMID: 10454567

5. McChesney PA, **Aisner DL**, Frank BC, Wright WE, Shay JW: Telomere dynamics in cells with introduced telomerase: a rapid assay for telomerase activity on telomeres. *Mol Cell Biol Res Commun* 2000, 3:312-8.PMID: 10964756
6. Yi X, White DM, **Aisner DL**, Baur JA, Wright WE, Shay JW: An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. *Neoplasia* 2000, 2:433-40. PMID: 11191110
7. **Aisner DL**, Maker A, Rosenberg SA, Berman DM: Loss of S100 antigenicity in malignant melanoma. *Hum Pathol* 2005, 36:1016– 1019.PMID: 16153466
8. O'Mahony D, Debnath I, Janik J, **Aisner D**, Jaffe E, Waldmann T, Morris J: Cardiac involvement with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: The NIH experience. *Leuk Lymphoma* 2008, 49:439-46. PMID: 18297519
9. Kleinschmidt-DeMasters BK, Birks DK, **Aisner DL**, Hankinson TC, Rosenblum MK: Atypical teratoid/rhabdoid tumor arising in a ganglioglioma: genetic characterization. *Am J Surg Path* 2011, 35: 1894-901PMID: 22082607
10. Sholl AB, **Aisner DL**, Behbakht K, Post MD: Novel TP53 gene mutation and correlation with p53 immunohistochemistry in a mixed epithelial carcinoma of the endometrium. *Gynecol Oncol Case Rep* 2012, 3:11-13 PMID: 24371653
11. **Aisner DL**, Deshpande C, Baloch Z, Watt CD, Litzky LA, Malhotra B, Sepulveda AR, Langer C, Evans T, Van Deerlin VM: Evaluation of EGFR mutation status in cytology specimens: An institutional experience. *Diag Cytopathol epub* 2011, DOI: 10.1002/dc.21851 (2013, 41(4): 316-23) PMID: 22102479
12. Doebele RC, Pilling AB, **Aisner DL**, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin Cancer Res* 2012, 18(5): 1472-82; DOI 10.1158/1078-0432.CCR-11-2906 PMID: 22235099
13. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, **Aisner DL**, Varella-Garcia M, Camidge DR: Oncogene status predicts pattern of metastatic spread in treatment-naive nonsmall cell lung cancer. *Cancer* 2012, DOI 10.1002/cncr.27409 PMID: 22282022
14. Schwartz LE, **Aisner DL**, Baloch ZW, Serman D, Vachani A, Gillespie C, Haas A, Litzky LA: The diagnostic efficacy of combining bronchoscopic tissue biopsy and endobronchial ultrasound-guided transbronchial needle aspiration for the diagnosis of malignant lesions in the lung. *Diag Cytopatho* 2012 DOI: 10.1002/dc.22847 PMID: 22362678
15. Davies KD, Le AT, Theodoro MF, Skokan MC, **Aisner DL**, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC: Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer. *Clin Cancer Res* 2012 DOI: 10.1158/1078-0432.CCR-12-0550 PMID: 22919003

16. Schmidt Y, Kleinschmidt-DeMasters BK, **Aisner DL**, Lillehei KO, Damek D: Anaplastic PXA in adults: case series with clinicopathologic and molecular features. *J Neurooncol* 2012 DOI: 10.1007/s11060-012-0991-4 PMID: 23096133
17. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, **Aisner DL**, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. *J Thorac Oncol* 2012 7(12): 1807 PMID: 23154552
18. Kleinschmidt-DeMasters BK, **Aisner DL**, Birks DK, Foreman NK: Epithelioid GBMs show a high percentage of BRAF V600E mutation. *Am J Surg Pathol* 2013, 37:685 PMID: 23552385
19. Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, Le P, Umpierrez A, Eagles-Soukup J, Gan GN, Vogler BW, Sehrt D, Takimoto SM, **Aisner DL**, Wilhelm F, Frederick BA, Varella-Garcia M, Tan AC, Jimeno A: The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. *Mol Cancer Ther* 2013, 12:1994-2005 PMID: 23873848
20. Berge EM, Aisner DL, Doebele RC: Erlotinib response in a NSCLC patient with a novel compound G719D + L861R mutation in EGFR. *J Thoracic Oncol* 2013, 8:e83-4 PMID: 23945392
21. Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, Barón AE, Schulte N, Maxson D, **Aisner DL**, Franklin WA, Doebele RC, Varella-Garcia M: Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. *Cancer* 2013, 119(22):3968-75; doi: 10.1002/cncr.28311 PMID: 24022839
22. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, **Aisner DL**, Pilling AB, Berge EM, Kim J, Sasaki H, Park SI, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC: Oncogenic and drug-sensitive *NTRK1* rearrangements in lung cancer. *Nat Med* 2013, 19:1469-72 PMID: 24162815
23. Donson AM, Kleinschmidt-Demasters BK, **Aisner DL**, Bemis LT, Birks DK, Levy JM, Smith AA, Handler MH, Foreman NK, Rush SZ: Pediatric Brainstem Gangliogliomas Show BRAF V600E Mutation in a High Percentage of Cases. *Brain Pathol* 2013, 24(2): 173-83; doi 10.1111/bpa.12103 PMID: 24238153
24. **Aisner DL**, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, Chionh F, Hardingham J, Mariadason J, Tebbutt N, Doebele RC, Weickhardt AJ, Varella-Garcia M: ROS1 and ALK Fusions in Colorectal Cancer with Evidence of Intra-Tumoral Heterogeneity for Molecular Drivers. *Mol Cancer Res* 2013, 12(1):111-8 PMID: 24296758
25. **Aisner DL**, Newell KL, Pollack AG, Kleinschmidt-Demasters BK, Steinberg GK, Smyth LT, Vogel H: Composite pleomorphic xanthoastrocytomepithelioid glioneuronal tumor with *BRAF* V600E mutation - report of three cases. *Clin Neuropathol* 2013, 33(2): 112-21 PMID: 24321241

26. Davies KD, Mahale S, Astling DP, **Aisner DL**, Le AT, Hinz TK, Vaishnavi A, Bunn PA Jr, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC: Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer. *PLoS One* 2013 8:e82236 PMID: 24349229
27. Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, **Aisner DL**, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, : Phase I Study of Oral Rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. *Clin Cancer Res*; 2014 20(6): 1656-65 PMID: 24493827
28. Ren S, Hirsch FR, Varella-Garcia M, **Aisner DL**, Boyle T, Zhou C, Camidge DR: Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. *J Thorac Oncol*; 9(3):e21-3 PMID: 24518095
29. Poonia S, Berge EM, **Aisner DL**, Damek D, Doebele RC: EGFR exon 19 deletion mutations and systemic/central nervous system military metastasis: clinical correlations and response to therapy. *Clin Lung Cancer* 2014; 15(5): 387-9 PMID: 24894944
30. Lummus SC, **Aisner DL**, Sams SB, Foreman NK, Lillehei KO, Kleinschmidt-DeMasters BK: Massive dissemination from spinal cord gangliogliomas negative for BRAF V600E: report of two rare adult cases. *Am J Clin Pathol* 2014; 142(2): 542-60 PMID: 25015869
31. Lio E, **Aisner DL**, Askin FB, Kwak JJ: Giant pulmonary chondroid hamartoma: imaging and pathology correlation of a rare tumor demonstrated with bone scintigraphy and 18F-FDG PET/CT. *Clin Nucl Med* 2015; 40(1):79-81 PMID: 25275419
32. Kleinschmidt-DeMasters BK, **Aisner DL**, Foreman NK: BRAF VE1 Immunoreactivity Patterns in Epithelioid Glioblastomas Positive for BRAF V600E Mutation. *Am J Surg Pathol* 2015; 39(4): 528-40 PMID: 25581727
33. Cargnelutti M, Corso S, Pergolizzi M, Mevellec L, **Aisner DL**, Dziadziuszko R, Varella-Garcia M, Comoglio PM, Doebele RC, Vialard J, Giordano S: Activation of RAS family members confers resistance to ROS1 targeting drugs. *Oncotarget* 2015; 6(7): 5182-94 PMID: 25691052
34. Sholl LM*, **Aisner DL***, Varella-Garcia M*, Berry LD*, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators: Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. *J Thorac Oncol* 2015; 10(5): 768-77 PMID: 25738220
35. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, **Aisner DL**, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR: Rociletinib in EGFR-

- mutated non-small-cell lung cancer. *N Engl J Med* 2015; 372(18):1700-9 PMID: 25923550
36. Becker AP, Scapulatempo-Neto C, Carloni AC, Paulino A, Sheren J, **Aisner DL**, Musselwhite E, Clara C, Machado HR, Oliveira RS, Neder L, Varella-Garcia M, Reis RM: KIAA1549:BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in pilocytic astrocytomas. *J Neuropathol Exp Neurol* 2015; 74(7): 743-54 PMID: 26083571
 37. O'Neil BH, Scott AJ, Ma WW, Cohen SJ, **Aisner DL**, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA: A Phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. *Ann Oncol* 2015 doi: 10.1093/annonc/mdv264 PMID: 26091808
 38. Doebele RD, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, **Aisner DL**, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low, JA: An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomyosin-related kinase (TRK) inhibitor LOXO-101. *Cancer Discov* 2015 doi: 10.1158/2159-8290.CD-15-0443
 39. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, **Aisner DL**, Vaishnavi A, Ou SI, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG: RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. *Nat Med* 2015 doi: 10.1038/nm.3930
 40. O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, **Aisner DL**, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. *Ann Oncol* 2015 Dec; 26(12):2505
 41. Li BT, Ross DS, **Aisner DL**, Chaft JE, Hsu M, Kako SL, Kris MG, Varella-Garcia M, Arcila ME. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. *J Thorac Oncol* 2016 Mar; 11(3) 414-9
 42. Sholl LM, **Aisner DL**, Allen TC, Beasley MB, Borczuk AC, Cagle PT, Capelozzi V, Dacic S, Hariri L, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhman N, Roy-Chowdhuri S, Thunnissen E, Tsao MS, Yatabe Y; Members of Pulmonary Pathology Society. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med* 2016 April 140(4): 341-4

43. **Aisner DL**, Berry A, Dawson DB, Hayden RT, Joseph L, Hill CE. A Suggested Molecular Pathology Curriculum for Residents: A Report of the Association for Molecular Pathology. *J Mol Diagn* 2016 March, 18(2): 153-162
44. O'Neil BH, Scott AJ, Ma WW, Cohen SJ, **Aisner DL**, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. *Ann Oncol*. 2016 Jun;27(6):1180
45. Siegele BJ, Shilo K, Chao BH, Carbone DP, Zhao W, Ioffe O, Franklin WA, Edelman MJ, **Aisner DL**. Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature. *Lung Cancer*. 2016 May;95:65-72
46. Dziadziuszko R, Le AT, Wrona A, Jassem J, Camidge DR, Varella-Garcia M, **Aisner DL**, Doebele RC. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. *J Thorac Oncol*. 2016 Aug;11(8):1273-81
47. Roy-Chowdhuri S, **Aisner DL**, Allen TC, Beasley MB, Borczuk A, Cagle PT, Capelozzi V, Dacic S, da Cunha Santos G, Hariri LP, Kerr KM, Lantuejoul S, Mino-Kenudson M, Moreira A, Raparia K, Rekhtman N, Sholl L, Thunnissen E, Tsao MS, Vivero M, Yatabe Y. Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med*. 2016 Apr 15
48. Patil T, **Aisner DL**, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. *Lung Cancer*. 2016 Jun;96:27-32
49. Davies KD, Farooqi MS, Gruidl M, Hill CE, Woolworth-Hirschhorn J, Jones H, Jones KL, Magliocco A, Mitui M, O'Neill PH, O'Rourke R, Patel NM, Qin D, Ramos E, Rossi MR, Schneider TM, Smith GH, Zhang L, Park JY, **Aisner DL**. Multi-Institutional FASTQ File Exchange as a Means of Proficiency Testing for Next-Generation Sequencing Bioinformatics and Variant Interpretation. *J Mol Diagn*. 2016 Jul;18(4):572-9
50. Sholl LM, **Aisner DL**, Allen TC, Beasley MB, Cagle PT, Capelozzi VL, Dacic S, Hariri LP, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao M, Vivero M, Yatabe Y. Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med*. 2016 Aug;140(8):825-9
51. Noonan SA, Berry L, Lu X, Gao D, Barón AE, Chesnut P, Sheren J, Aisner DL, Merrick D, Doebele RC, Varella-Garcia M, Camidge DR. Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. *J Thorac Oncol*. 2016 Aug;11(8):1293-304
52. Raparia K, **Aisner DL**, Allen TC, Beasley MB, Borczuk A, Cagle PT, Capelozzi V, Dacic S, Hariri LP, Kerr KM, Lantuejoul S, Mino-Kenudson M, Rekhtman N, Roden

- AC, Roy-Chowdhuri S, Sholl L, Smith ML, Thunnissen E, Tsao MS, Yatabe Y. Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med*. 2016 Jul 21
53. **Aisner DL**, Rumery MD, Merrick DT, Kondo KL, Nijmeh H, Linderman DJ, Doebele RC, Thomas N, Chesnut PC, Varella-Garcia M, Franklin WA, Camidge DR. Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. *Arch Pathol Lab Med*. 2016 Sep 9
54. Roden AC, **Aisner DL**, Allen TC, Aubry MC, Barrios RJ, Beasley MB, Cagle PT, Capelozzi VL, Dacic S, Ge Y, Hariri LP, Lantuejoul S, Miller RA, Mino-Kenudson M, Moreira AL, Raparia K, Rekhtman N, Sholl L, Smith ML, Tsao MS, Vivero M, Yatabe Y, Yi ES. Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies: A Perspective From Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med*. 2017 Mar;141(3):437-444
55. Gao B, Huang C, Kernstine K, Pelekanou V, Kluger Y, Jiang T, Peters-Hall JR, Coquelin M, Girard L, Zhang W, Huffman K, Oliver D, Kinose F, Haura E, Teer JK, Rix U, Le AT, **Aisner DL**, Varella-Garcia M, Doebele RC, Covington KR, Hampton OA, Doddapaneni HV, Jayaseelan JC, Hu J, Wheeler DA, Shay JW, Rimm DL, Gazdar A, Minna JD. Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. *Oncotarget*. 2017 Feb 14;8(7):11114-11126
56. Mulcahy Levy JM, Zahedi S, Griesinger AM, Morin A, Davies KD, **Aisner DL**, Kleinschmidt-DeMasters BK, Fitzwalter BE, Goodall ML, Thorburn J, Amani V, Donson AM, Birks DK, Mirsky DM, Hankinson TC, Handler MH, Green AL, Vibhakar R, Foreman NK, Thorburn A. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. *Elife*. 2017 Jan 17;6.
57. York ER, Varella-Garcia M, Bang TJ, **Aisner DL**, Camidge DR. Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2017 Mar 6.
58. Ettinger DS, Wood DE, **Aisner DL**, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. *J Natl Compr Canc Netw*. 2017 Apr;15(4):504-535
59. Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar S, Glogowska MJ, Smith MA, Kako SL, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, **Aisner DL**, Doebele RC. EGFR mediates responses to small molecule drugs targeting oncogenic fusion kinases. *Cancer Res*. 2017 Apr 20.
60. Thunnissen E, Allen TC, Adam J, **Aisner DL**, Beasley MB, Borczuk AC, Cagle PT, Capelozzi VL, Cooper W, Hariri LP, Kern I, Lantuejoul S, Miller R, Mino-Kenudson

- M, Radonic T, Raparia K, Rekhtman N, Roy-Chowdhuri S, Russell P, Schneider F, Sholl LM, Tsao MS, Vivero M, Yatabe Y. Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med*. 2017 Jul 7
61. Davies KD, Ng TL, Estrada-Bernal A, Le AT, Ennever PR, Camidge DR, Doebele RC, **Aisner DL**. Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion. *JCO Precis Oncol*. 2017;2017(1):PO.17.00117. doi: 10.1200/PO.17.00117. Epub 2017 Aug 29.
62. Reeser JW, Martin D, Miya J, Kautto EA, Lyon E, Zhu E, Wing MR, Smith A, Reeder M, Samorodnitsky E, Parks H, Naik KR, Gozgit J, Nowacki N, Davies KD, Varella-Garcia M, Yu L, Freud AG, Coleman J, **Aisner DL**, Roychowdhury S. Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors. *J Mol Diagn*. 2017 Sep;19(5):682-696
63. Balla A, Hampel KJ, Khan F, **Aisner DL**, Sidiropoulos N. Small Cell Transformation of ALK-rearranged Non-Small Cell Adenocarcinoma of the Lung. *Cold Spring Harb Mol Case Stud*. 2018 Jan 9
64. Jain D, Allen TC, **Aisner DL**, Beasley MB, Cagle PT, Capelozzi VL, Hariri LP, Lantuejoul S, Miller R, Mino-Kenudson M, Monaco SE, Moreira A, Raparia K, Rekhtman N, Roden AC, Roy-Chowdhuri S, da Cunha Santos G, Thunnissen E, Tronccone G, Vivero M. Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med*. 2018 Feb; 142(2): 253-262
65. Lindeman NI, Cagle PT, **Aisner DL**, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *J Thorac Oncol*. 2018 March; 13(3): 323-358
66. Lindeman NI, Cagle PT, **Aisner DL**, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *J Mol Diagn*. 2018 March; 20(2): 129-159
67. Lindeman NI, Cagle PT, **Aisner DL**, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated Molecular Testing Guideline for the Selection of

Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *Arch Pathol Lab Med.* 2018 March; 142 (3): 321-346

68. **Aisner DL**, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations – The Lung Cancer Mutation Consortium (LCMC2). *Clin Cancer Res.* 2018 March; 24(5): 1038-1047
69. Thunnissen E, Allen TC, Adam J, **Aisner DL**, Beasley MB, Borczuk AC, Cagle PT, Capelozzi VL, Cooper W, Hariri LP, Kern I, Lantuejoul S, Miller R, Mino-Kenudson M, Radonic T, Raparia K, Rekhtman N, Roy-Chowdhuri S, Russell P, Schneider F, Sholl LM, Tsao MS, Vivero M, Yatabe Y. Immunohistochemistry of Pulmonary Biomarkers: A Perspective from Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med.* 2018 March; 142(3): 408-419
70. McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, **Aisner DL**, Davies KD, Lanman RB, Shaw AT, Doebele, RC. Clinical Utility of Cell-Free DNA for the Detection of *ALK* Fusions and Genomic Mechanisms of *ALK* Inhibitor Resistance in Non-Small Cell Lung Cancer. *Clin Cancer Res.* 2018 Jun 24(12):2578-2770
71. McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, **Aisner DL**, Camidge DR, Doebele RC. Resistance Mechanisms to Targeted Therapies In ROS1(+) and ALK(+) Non-small Cell Lung Cancer. *Clin Cancer Res.* 2018 Apr 10
72. Kang W, Kadri S, Puranik R, Wurst MN, Patil SA, Mujacic I, Benhamed S, Niu N, Zhen CJ, Ameti B, Long BC, Galbo F, Montes D, Iracheta C, Gamboa VL, Lopez D, Yourshaw M, Lawrence CA, **Aisner DL**, Fitzpatrick C, McNerney ME, Wang YL, Andrade J, Volchenboum SL, Furtado LV, Ritterhouse LL, Segal JP. System for Informatics in the Molecular Pathology Laboratory: An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management. *J Mol Diagn.* 2018 Jul;20(4):522-532.
73. Davies KD, Le AT, Sheren J, Nijmeh H, Gowan K, Jones KL, Varella-Garcia M, **Aisner DL**, Doebele RC. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. *J Thorac Oncol.* 2018 Jun 20
74. Patil T, Smith DE, Bunn PA, **Aisner DL**, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. *J Thorac Oncol.* 2018 Nov;13(11):1717-1726. PubMed PMID: 29981925

75. Ettinger DS, **Aisner DL**, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. *J Natl Compr Canc Netw*. 2018 Jul;16(7):807-821. PubMed PMID: 30006423
76. Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, **Aisner D**, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. *Breast Cancer Res*. 2018 Aug 2;20(1):82. PubMed PMID: 30071865
77. Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, Kane M, Tan AC, Wang XJ, Jimeno A, **Aisner DL**, Bowles DW, Raben D. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. *Clin Cancer Res*. 2018 Oct 15;24(20):4949-4959. PubMed PMID: 30084837
78. Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, **Aisner DL**, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. *JCO Precis Oncol*. 2018;2018. PubMed PMID: 30215037
79. Brown NA, **Aisner DL**, Oxnard GR. Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. *Am Soc Clin Oncol Educ Book*. 2018 May 23;(38):708-715. PubMed PMID: 30231309
80. Blumenthal GM, Bunn PA Jr, Chافت JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, **Aisner DL**, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruyscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. *J Thorac Oncol*. 2018 Dec;13(12):1818-1831. PubMed PMID: 30268698
81. Ng TL, Smith DE, Mushtaq R, Patil T, Dimou A, Yang S, Liu Q, Li X, Zhou C, Jones RT, Tu MM, Yan F, Bowman IA, Liu SV, Newkirk S, Bauml J, Doebele RC, **Aisner DL**, Gao D, Ren S, Camidge DR. ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. *J Thorac Oncol*. 2018 Dec 10. PubMed PMID: 30543838
82. Ng TL, Liu Y, Dimou A, Patil T, **Aisner DL**, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, Camidge DR. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1

- inhibitors in patients with oncogene-driven non-small cell lung cancer. *Cancer*. 2018 Dec 11. PubMed PMID: 30548240
83. Hernandez AL, Wang Y, Somerset HL, Keysar SB, **Aisner DL**, Marshall C, Bowles DW, Karam SD, Raben D, Jimeno A, Varella-Garcia M, Wang XJ. Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas. *Mol Carcinog*. 2018 Dec 21. PubMed PMID: 30575147
 84. Pacheco JM, Gao D, Smith D, Purcell WT, Hancock M, Bunn PA, Robin TP, Liu AK, Karam S, Gaspar LE, Kavanagh BD, Rusthoven CG, **Aisner DL**, Doebele RC, Camidge DR. Natural history and factors associated with overall survival in stage IV ALK rearranged non-small-cell lung cancer. *J Thorac Oncol*. 2018 Dec 29. PubMed PMID: 30599201
 85. Davies KD, Lomboy A, Lawrence CA, Yourshaw M, Bocsi GT, Camidge DR, **Aisner DL**. Brief Report: DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer. *J Thorac Oncol*. 2019 Jan 9. PMID: 30639620
 86. Ng TL, Yu H, Smith DE, Boyle TA, York ER, Leedy S, Gao D, **Aisner DL**, Van Bokhoven A, Heasley LE, Hirsch FR, Camidge DR. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. *Clin Lung Cancer*. 2019 Jan;20(1):e39-e51
 87. El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, Sholl LM, **Aisner DL**, Bunn PA, Khuri FR, Ramalingam SS. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. *J Thorac Oncol*. 2019 May;14(5):876-889. doi: 10.1016/j.jtho.2019.01.020. Epub 2019 Feb 5. PubMed PMID: 30735816.
 88. Guo R, Berry LD, **Aisner DL**, Sheren J, Boyle T, Bunn PA Jr, Johnson BE, Kwiatkowski DJ, Drilon A, Sholl LM, Kris MG. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. *J Thorac Oncol*. 2019 Sep;14(9):1666-1671. doi: 10.1016/j.jtho.2019.06.009. Epub 2019 Jun 20. PubMed PMID: 31228623
 89. Seager M, **Aisner DL**, Davies KD. Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing. *J Vis Exp*. 2019 Jul 5;(149). doi: 10.3791/59895. PubMed PMID: 31329176.
 90. Ettinger DS, Wood DE, Aggarwal C, **Aisner DL**, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K; OCN, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. *J Natl Compr Canc Netw*. 2019 Dec;17(12):1464-1472
 91. Sirohi D, Schmidt RL, **Aisner DL**, Behdad A, Betz BL, Brown N, Coleman JF, Corless CL, Deftereos G, Ewalt MD, Fernandes H, Hsiao SJ, Mansukhani MM, Murray SS, Niu N, Ritterhouse LL, Suarez CJ, Tafe LJ, Thorson JA, Segal JP, Furtado LV. Multi-

Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. *J Mol Diagn.* 2019 Dec 16. pii: S1525-1578(19)30435-0

92. Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, **Aisner DL**, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. *Clin Lung Cancer.* 2019 Nov 21.
93. Tsongalis GJ, Al Turkmani MR, Suriawinata M, Babcock MJ, Mitchell K, Ding Y, Scicchitano L, Tira A, Buckingham L, Atkinson S, Lax A, **Aisner DL**, Davies KD, Wood HN, O'Neill SS, Levine EA, Sequeira J, Harada S, DeFrank G, Paluri R, Tan BA, Colabella H, Snead C, Cruz-Correa M, Ramirez V, Rojas A, Huang H, Mackinnon AC, Garcia FU, Cavone SM, Elfahal M, Abel G, Vasef MA, Judd A, Linder MW, Alkhateeb K, Skinner WL, Boccia R, Patel K. Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer. *Am J Clin Pathol.* 2020 Jul 7;154(2):266-276. doi: 10.1093/ajcp/aqaa044. PMID: 32525522.
94. Grob ST, Nobre L, Campbell KR, Davies KD, Ryall S, **Aisner DL**, Hoffman L, Zahedi S, Morin A, Crespo M, Nellan A, Green AL, Foreman N, Vibhakar R, Hankinson TC, Handler MH, Hawkins C, Tabori U, Kleinschmidt-DeMasters BK, Mulcahy Levy JM. Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. *Neurooncol Adv.* 2020 Aug 24;2(1):vdaa103. doi: 10.1093/noajnl/vdaa103. PMID: 33063010; PMCID: PMC7542983.
95. Holman BN, Van Gulick RJ, Amato CM, MacBeth ML, Davies KD, **Aisner DL**, Robinson WA, Coutts KL. Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. *Melanoma Res.* 2020 Dec; 30(6):562-573. doi: 10.1097/CMR.0000000000000688. PMID: 33156595.
96. Ettinger DS, Wood DE, **Aisner DL**, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, J Dowell, Gettinger S, Gubens MA, Hedge A, Hennon M, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Lovly, CM, Martins RG, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Riely GJ, Schild SE, Shapiro TA, Singh AP, Stevenson J, Swanson SJ, Tam A, Yanagawa J, Yang SC, Gregory K; OCN, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. *J Natl Compr Canc Netw.* 2019 Dec;17(12):1464-1472
97. Tsui DCC, **Aisner D**, Nijmeh H, Bao L, Menter A, Camidge DR: Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. *Clin Lung Cancer.* 2021; doi: 10.1016/j.clcc.2021.06.012
98. Peters TL, Patil T, Le AT, Davies KD, Brzeskiewicz PM, Nijmeh H, Bao L, Camidge DR, **Aisner DL**, Doebele RC. Evolution of MET and NRAS gene amplification as

- acquired resistance mechanisms in EGFR mutant NSCLC. *NPJ Precis Oncol*. 2021 Oct 12;5(1):91. doi: 10.1038/s41698-021-00231-x. PMID: 34642436.
99. Colton MD, Tompkins K, O'Donnell E, **Aisner D**, Lieu CH, Konnick EQ, Fishbein L. Case of Metastatic Pheochromocytoma and Meningiomas in a Patient With Lynch Syndrome. *JCO Precis Oncol*. 2022 Jan;6:e2100251. doi: 10.1200/PO.21.00251. PMID: 35025617.
 100. Patil T, Nie Y, **Aisner DL**, Camidge DR. Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology. *Front Oncol*. 2022 Jan 7;11:788245. doi: 10.3389/fonc.2021.788245. PMID: 35070994; PMCID: PMC8777186.
 101. Ettinger DS, Wood DE, **Aisner DL**, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025. PMID: 35545176.
 102. Furtado LV, Souers RJ, Vasalos P, Halley JG, **Aisner DL**, Nagarajan R, Voelkerding KV, Merker JD, Konnick EQ. Four-Year Laboratory Performance of the First College of American Pathologists In Silico Next-Generation Sequencing Bioinformatics Proficiency Testing Surveys. *Arch Pathol Lab Med*. 2022 Jun 7. doi: 10.5858/arpa.2021-0384-CP. Epub ahead of print. PMID: 35671151.
 103. Hong ES, Messersmith WA, Hammad H, Cornish TC, **Aisner DL**. Tissue Displacement Versus Two Primary Colorectal Carcinomas? A Case Report on the Utility of Comparative Sequencing. *JCO Precis Oncol*. 2022 Oct;6:e2200252. doi: 10.1200/PO.22.00252. PMID: 36240469; PMCID: PMC9616644.
 104. Hall KC, Post MD, Alldredge J, **Aisner DL**, Berning A. Molecular Evidence for Epithelial Origin of Mixed Ovarian Epithelial-Germ Cell Neoplasms: Report of 2 Cases and Review of Literature. *Int J Gynecol Pathol*. 2022 Oct 28. doi: 10.1097/PGP.0000000000000913. Epub ahead of print. PMID: 36305517.
 105. Wang S, Rong R, Yang DM, Fujimoto J, Bishop JA, Yan S, Cai L, Behrens C, Berry LD, Wilhelm C, **Aisner D**, Sholl L, Johnson BE, Kwiatkowski DJ, Wistuba II, Bunn PA Jr, Minna J, Xiao G, Kris MG, Xie Y. Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. *J Clin Invest*. 2023 Jan 17;133(2):e160330. doi: 10.1172/JCI160330. PMID: 36647832; PMCID: PMC9843059.
 106. Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis GB, Mandell M, Davies KD, Lawrence C, O'Donnell E, Doebele RC, Bao L, **Aisner DL**, Schenk EL. Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. *NPJ Precis Oncol*. 2023 Jan 23;7(1):9. doi: 10.1038/s41698-023-00349-0. PMID: 36690705; PMCID: PMC9871013.

107. Ettinger DS, Wood DE, **Aisner DL**, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. *J Natl Compr Canc Netw*. 2023 Apr;21(4):340-350. doi: 10.6004/jnccn.2023.0020. PMID: 37015337.
108. Lee TD, **Aisner DL**, David MP, Eno CC, Gagan J, Gocke CD, Guseva NV, Haley L, Jajosky AN, Jones D, Mansukhani MM, Mroz P, Murray SS, Newsom KJ, Paulson V, Roy S, Rushton C, Segal JP, Senaratne TN, Siddon AJ, Starostik P, Van Ziffle JAG, Wu D, Xian RR, Yohe S, Kim AS. Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report. *Blood Adv*. 2023 Aug 22;7(16):4599-4607. doi: 10.1182/bloodadvances.2023010149. PMID: 37236162; PMCID: PMC10425685.
109. **Aisner DL**, Gocke CD, Jones D, Limson M, Morrissette J, Segal JP. The Genomics Organization for Academic Laboratories (GOAL): A vision for a genomics future for academic pathology. *Acad Pathol*. 2023 Aug 8;10(3):100090. doi: 10.1016/j.acpath.2023.100090. PMID: 37583476; PMCID: PMC10424130.
110. Schreiber AR, Santos J, McMahon B, Buckner TW, Olson C, Alberti MO, Guimarães-Young A, Knoeckel C, Broussard L, Aubrey M, Palmer BE, Weiss E, Connors GR, Brunner S, Wisell JA, Pacheco T, **Aisner DL**, Gutman JA. A Case of Fetal-Induced Graft-versus-Host Disease. *N Engl J Med*. 2023 Aug 17;389(7):668-670. doi: 10.1056/NEJMc2307669. PMID: 37585636.
111. Ettinger DS, Wood DE, Stevenson J, **Aisner DL**, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Shapiro TA, Singh AP, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2023 Sep;21(9):961-979. doi: 10.6004/jnccn.2023.0045. PMID: 37673108.
112. Davies KD, Smith LP, Guimaraes-Young A, Corr BR, Fisher CM, Guntupalli SR, Berning AA, Post MD, Pino D, **Aisner DL**, Wolsky RJ. Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center. *Int J Gynecol Pathol*. 2023 Oct 4. doi: 10.1097/PGP.0000000000000994. Epub ahead of print. PMID: 37922951.
113. Jurica JM, Carsten B, Balakhani S, Haag MM, **Aisner DL**, Camidge DR. CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS Progression. *Clin Lung Cancer*. 2024 Jan;25(1):77-79. doi: 10.1016/j.clcc.2023.09.004. Epub 2023 Oct 4. PMID: 37932178.

Review articles (peer reviewed, including invited reviews):

1. **Aisner DL**, Wright WE, Shay JW: Telomerase regulation: not just flipping the switch. *Curr Opin Genet Dev.* 2002, 12:80-5. PMID: 11790559
2. **Aisner DL**, Theodorescu D: Genetic testing for metastasis: potential for improved cancer treatment. *Future Oncol* 2011, 7:697-701 PMID: 21675831
3. Dancik G, **Aisner DL**, Theodorescu D: A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. *PLoS Curr.* 2011, 3:RRN1248 PMID: 21858252
4. **Aisner DL** and Sams SB: The Role of Cytopathology Specimens in Molecular Testing of Solid Tumors: Techniques, Limitations and Opportunities. *Diag Cytopathology.* 2012 doi: 10.1002/dc.22820 PMID: 22619126
5. **Aisner DL** and Marshall CB: Molecular pathology of non-small cell lung cancer: a practical guide. *Am J Clin Pathol.* 2012, 138:332 PMID: 22912349
6. Weickhardt AJ, **Aisner DL**, Franklin WA, Varella-Garcia M, Doebele RC, Camidge DR: Diagnostic Assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. *Cancer* 2012 DOI 10.1002/ncr.27913 PMID: 23280244
7. Tai D, Wells K, Arcaroli J, Vanderbilt C, **Aisner DL**, Messersmith WA, Lieu CH: Targeting the WNT Signaling Pathway in Cancer Therapeutics. *Oncologist.* 2015 PMID: 26306903
8. Hsiao SJ, Zehir A, Sireci AN, **Aisner DL**. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. *J Mol Diagn.* 2019 Jul;21(4):553-571. doi: 10.1016/j.jmoldx.2019.03.008. Epub 2019 May 7. Review. PubMed PMID: 31075511.
9. Sireci AN, Patel JL, Joseph L, Hiemenz MC, Rosca OC, Caughron SK, Thibault-Sennett SA, Burke TL, **Aisner DL**. Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement: A Report of the Association for Molecular Pathology. *J Mol Diagn.* 2020 Aug;22(8):975-993. doi: 10.1016/j.jmoldx.2020.05.008.
10. Herbst, RS, **Aisner DL**, Sonett J, Turk AT, Weintraub JL, Lindeman NI: Practical Considerations Relating to Routine Clinical Biomarker Testing for Non-small Cell Lung Cancer: Focus on Testing for RET Fusions. *Front Med.* 2021 Jan; 7:562480
11. Rasti AR, Guimaraes-Young A, Datko F, Borges VF, **Aisner DL**, Shagisultanova E. *PIK3CA* Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. *JCO Precis Oncol.* 2022 Mar;6:e2100370. doi: 10.1200/PO.21.00370. PMID: 35357905; PMCID: PMC8984255.

Invited Editorials

1. Franklin WA, **Aisner DL**, Varella-Garcia M: Prognostic Patterns in the Histopathology of Pulmonary Adenocarcinoma. *J Clin Oncol.* 2012 PMID: 22393082
2. Bunn PA, Hirsch FR, **Aisner DL**: Is there clinical value to prognostic signatures in early-stage NSCLC? *Clin Cancer Res.* 2014; 20(7): 1727-9 PMID: 24583801

3. Davies KD, Doebele RD, **Aisner DL**: Rearranging Detection of Rearrangements. *J Thorac Oncol*. 2015; 10(8):1129-30 PMID: 26200265
4. **Aisner DL**: The Revised College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline: A Step Forward for Molecular Cytopathology. *Arch Pathol Lab Med*. 2018 142(6):684-685
5. Bunn PA, **Aisner DL**: Broad-based Molecular Testing for Lung Cancer: Precisely the Time for Precision, *JAMA*. 2018 Aug 7;320(5):445-446.
6. Davies KD, Villalobos VM, **Aisner DL**. Ready or Not, Here I Come: Inflammatory Myofibroblastic Tumors With Kinase Alterations Revealed Through Molecular Hide and Seek. *J Thorac Oncol*. 2019 May;14(5):758-760. doi:10.1016/j.jtho.2019.02.006. PubMed PMID: 31027738
7. Davies KD, **Aisner DL**. Wake Up and Smell the Fusions: Single-Modality Molecular Testing Misses Drivers. *Clin Cancer Res*. 2019 Aug 1;25(15):4586-4588. doi: 10.1158/1078-0432.CCR-19-1361. Epub 2019 Jun 3. PubMed PMID: 31160470

Books and Book Chapters

1. Roundtable on Evidence Based Medicine: The Learning Healthcare System Workshop Summary ed. Olsen L, **Aisner D**, JM McGinnis; National Academies Press, Washington, D.C., 2007
2. Sepulveda AR and **Aisner DL**: Molecular Basis of Diseases of the Gastrointestinal Tract. In *Molecular Pathology: The Molecular Basis of Human Disease* by Coleman WB and Tsongalis GJ; Academic Press, Burlington, MA, 2009 pp365-394.
3. Serracino H, Franklin WA and **Aisner DL**: Molecular Pathology of Non-Small Cell Lung Cancer, In *Surgical Pathology Clinics: Molecular Oncology* by Hunt JL, Elsevier, Philadelphia, PA 2012, 5(4) pp903-918.
4. Franklin WA, **Aisner DL**, Post M, Bunn PA , Varella-Garcia M : Pathology, Biomarkers and Molecular Diagnostics. In *Abeloff's Clinical Oncology* by Niederhuber JE, Armitage JO et al., Elsevier Saunders, Philadelphia, PA, 2014 pp226-252.
5. **Aisner DL** , Doebele RC, Varella-Garcia M, Fraklin WA : Molecular Pathology of Lung Cancer. In *Molecular Pathology in Clinical Practice* by Leonard, 2016, pp.419-432.
6. Hsiao SJ, **Aisner DL**, Ewalt MD: Clinical NGS assays for solid tumors: current practices, technological advances and challenges in clinical practice. In *Advances in Molecular Pathology* Volume 1, 1st Edition, Elsevier, Inc. Philadelphia, PA. Chapter 15, 2018.
7. Willard N, Sholl L, **Aisner D**. Panel Sequencing for Targeted Therapy Selection in Solid Tumors. *Clin Lab Med*. 2022 Sep;42(3):309-323. doi: 10.1016/j.cll.2022.04.004. Epub 2022 Aug 22. PMID: 36150814.

Practice Standards

Clinical and Laboratory Standards Institute. Molecular Methods for Solid Tumors (nonhematologic Neoplasms). 1st ed. CLSI guideline MM23. Wayne, PA: Clinical and Laboratory Standards Institute, 2015 (credited contributor and author)

White Papers

A Molecular Diagnostic Perfect Storm: The Convergence of Regulatory & Reimbursement Forces that Threaten Patient Access to Innovations in Genomic Medicine; Pratt VM, Aisner DL, Day SP, Joseph L, Melton SD, Rothberg PG, Sabath DE, Williams M. Published electronically at AMP.org:

http://www.amp.org/publications_resources/position_statements_letters/PerfectStorm.cfm
http://www.amp.org/publications_resources/position_statements_letters/documents/PerfectStorm-FINAL-CD.pdf

Charting the Course for Precision Medicine: Adopting consensus analytical standards and streamlining approval pathways for post-market modifications for NGS tests in oncology; Friends of Cancer Research, Published electronically at:

https://www.focr.org/sites/default/files/pdf/Friends_Alexandria%20White%20Paper_Final.pdf

Patient Education Materials

‘Pathology/Molecular Pathology 101: What Do the Terms Mean? (part 1)’: Podcast on Global Resource for Advancing Cancer Education (GRACE) website, November 30, 2012:

<http://cancergrace.org/cancer-101/2012/11/30/path-and-mol-pat/>

‘Pathology/Molecular Pathology 101: Practical Challenges in Testing (Part 2)’ Podcast on Global Resource for Advancing Cancer Education (GRACE) website, December 4, 2012:

<http://cancergrace.org/cancer-101/2012/12/04/aisner-practical-challenges-molec-testing/>

‘Pathology/Molecular Pathology 101: A Glimpse Into the Future (Part 3)’ Podcast on Global Resource for Advancing Cancer Education (GRACE) website, December 11, 2012:

<http://cancergrace.org/cancer-101/2012/12/11/dr-aisner-offers-glimpse-into-the-future-of-molecular-testing/>

‘Q & A about Lung Cancer Molecular Testing’ Talkabouthealth.com, September, 2013:

<http://talkabouthealth.com/DaraAisnerMDPhD>

‘Lung Cancer Living Room’ an Open Patient-Centered Q&A with specialists, August, 2018, video available at:

<https://vimeo.com/lungcancerlivingroom/lung-cancer-living-room>
<https://www.youtube.com/watch?v=OdS6JpfAcWc&t=5s>

Ewalt MD, West H, **Aisner DL**. Next Generation Sequencing-Testing Multiple Genetic Markers at Once. JAMA Oncol. 2019 Jul 1;5(7):1076. doi:10.1001/jamaoncol.2019.0453. PubMed PMID: 31145416.

Media (selected)

Features in the ASCO Post, August, 2014 <https://ascopost.com/issues/august-15-2014/getting-results-how-oncologists-and-pathologists-can-work-together-to-facilitate-molecular-testing/>

Resident case report at AMP meeting highlighted in CAP today, January, 2016:
<https://www.captodayonline.com/cases-focus-alk-false-negs-post-transplant-tumor/>

Featured in Genomeweb.com coverage of FDA session on regulation of laboratory developed tests, February, 2016: <https://www.genomeweb.com/molecular-diagnostics/workshop-fda-gathers-input-how-regulate-ngs-panels-guide-cancer-treatment#.YRq9JohKiUk>

Highlighted in CAP Today related to published article, May 2017:
<https://www.captodayonline.com/integrating-cytology-samples-molecular-testing-tumors/>

Highlighted in Newswise.com and other outlets related to published article, December 2017:
<https://www.newswise.com/articles/even-smokers-may-benefit-from-targeted-lung-cancer-treatments>

Featured on the cover of CAP Today, March, 2018 ‘Lung guideline goals: more tests, treatment’
<https://www.captodayonline.com/lung-guideline-goals-tests-treatment/>

Quoted/interviewed related to an editorial co-authored in JAMA ‘Broad-based molecular testing for NSCLC’ September, 2018 <https://www.captodayonline.com/put-board-0918/>

Interviewed for Colorado Cancer Blog, January, 2018, <https://coloradocancerblogs.org/expert-panel-issues-new-guidelines-lung-cancer-molecular-testing/>

Featured on CUAnschutz.com related to COVID-19 serology efforts:
<https://news.cuanschutz.edu/news-stories/cu-anschutz-scientists-join-search-for-covid-19-secret-wanderers>; <https://news.cuanschutz.edu/cancer-center/covid-19-proteins-antibody-testing>; <https://news.cuanschutz.edu/news-stories/cu-anschutz-researchers-roll-out-antibody-test>

The Colorado Bioscience Association (CBSA) feature on the CMOCO lab:
<https://cobioscience.com/the-colorado-molecular-correlates-laboratory-puts-quality-first/>

Anschutz Medical Campus news (CU Anschutz Today) page featured the GOAL consortium:
<https://news.cuanschutz.edu/cancer-center/goal-consortium-academic-pathology-testing-labs>

Scientific Abstracts Presented at Scientific Meetings

1. Love HD, Soltaninasaab S, McAfee J, **Aisner DL**, LeStourgeon W: hnRNP C proteins exist as a 390KDa dodecamer which binds 690nts of RNA during hnRNP assembly. Poster presentation at: *RNA Processing Cold Spring Harbor*, January, 1995.

2. **Aisner DL**, McChesney PA, Iucu CT, Baur JA, Wright WE, Shay JW: Characterization of putative phosphorylation sites and variants of the catalytic protein component of telomerase, poster presentation at: *Telomeres and Telomerase Symposium, Cold Spring Harbor*, January, 2001.
3. **Aisner DL**, Berman DM, Maker A, Rosenberg S: Loss of S100 antigenicity in malignant melanoma, platform presentation at: *USCAP 2005*, San Antonio, Texas
4. **Aisner DL**, Yao Y, Wen Y, Sepulveda AR: Progressive increase of MGMT (O6-methylguanine DNA methyltransferase) CpG methylation levels from colitis to low-grade dysplasia in ulcerative colitis, poster presentation at: *Digestive Diseases Week 2009*, Chicago, Illinois
5. Nielsen D, Strubinger J, McGrath C, Watt CD, **Aisner D**, Van Deerlin VM: Clinical performance of Invader v2 ASR assay and correlation with HPV genotyping, poster presentation at: *Association for Molecular Pathology Annual Meeting*, November 2009, Orlando, Florida
6. **Aisner DL**, Yao Y, Wen Y, Sepulveda AR: Increasing CpG methylation in a four gene panel during progression of ulcerative colitis to dysplasia, poster presentation at: *Association for Molecular Pathology Annual Meeting*, November 2009, Orlando, Florida
7. Ochs RC, **Aisner DL**, Sepulveda AR, Van Deerlin VM, Watt CD: Complex workflow in solid-tumor molecular diagnostics: implementing methods to improve turn-around time, poster presentation at: *Association for Molecular Pathology Annual Meeting*, November, 2010, San Jose, California
8. Edwards J, Goyal A, Watt CD, Baloch Z, Van Deerlin VM, **Aisner DL**: The effects of specimen preservative of pyrosequencing based assay for BRAF V600E in thyroid fine needle aspirate specimens: a clinical validation study, poster presentation at: *Association for Molecular Pathology Annual Meeting*, November, 2010, San Jose, California
9. **Aisner DL**, Deshpande C, Baloch Z, Watt CD, Litzky LA, Sepulveda AR, Langer C, Evans T and Van Deerlin VM: Adequacy of Limited Cellularity Specimens for EGFR Mutational Analysis, poster presentation at: *Association for Molecular Pathology Annual Meeting*, November, 2010, San Jose, California
10. Ende L, **Aisner DL**, Baloch Z, Serman D, Vachani A, Gillespie C, Haas A, Litzky LA: The diagnostic efficacy of combining bronchoscopic tissue biopsy and endobronchial ultrasound-guided fine needle aspiration for the diagnosis of malignant tumors in the lung, poster presentation at: *United States and Canadian Academy of Pathology Annual Meeting*, February, 2011, San Antonio, Texas
11. Franklin W, Haney J, Korch C, **Aisner DL**, Bunn P: Concurrent TP53 and tyrosine kinase signaling pathway mutations in adenocarcinoma of lung, poster presentation at: *International Association for the study of Lung Cancer World Conference on Lung Cancer*, July, 2011, Amsterdam, Netherlands
12. Doebele RC, Sumey CJ, Maxson DA, Lu X, Baron AE, Oton AB, Bunn PA, Varella-Garcia M, **Aisner DL**, Franklin WA, Camidge DR: Oncogene status predicts patterns of metastatic spread in treatment-naive lung cancer, at: *International Association for*

- the Study of Lung Cancer World Conference on Lung Cancer*, July, 2011, Amsterdam, Netherlands
13. Varella-Garcia M, Iafrate JA, Pao W, Berry L, Jhanwar S, Koehler E, **Aisner DL**, Kris MG, Franklin W, Shyr Y, Kwiatkowski D, Bunn P, Ladanyi M: ALK fusion and MET amplification as molecular biomarkers and therapeutic targets in advanced lung adenocarcinomas in the Lung Cancer Mutation Consortium, oral presentation at: *International Association for the Study of Lung Cancer World Conference on Lung Cancer*, July, 2011, Amsterdam, Netherlands
 14. Tyler KL, Torkko K, Camidge DR, Doebele RC, Franklin W, **Aisner DL**: Mutations are detected at comparable frequencies in a variety of specimen types in non-small cell lung carcinoma, oral presentation at: *International Association for the Study of Lung Cancer World Conference on Lung Cancer*, July, 2011, Amsterdam, Netherlands
 15. Bohn JJ, Haney J, Chesnut PC, Councilman KC, Thomas N, Said S, Klopper JP, Haugen BR, Franklin WA, **Aisner DL**: Microdissection of Cytology Diff-Quik Smears as a Source of Cellular Material for BRAF Mutational Analysis in Thyroid Fine Needle Aspirates, poster presentation at: *Association of Molecular Pathology Annual Meeting*, Grapevine, TX, November, 2011
 16. Pillai J, Boyle T, Chesnut PC, Thomas N, Bohn JJ, Leonard MJ, Aikens R, Franklin WA, **Aisner DL**: Paraffin Block Core Punching is an Effective Method for Tumor Enrichment for Solid Tumor Mutational Studies, poster presentation at: *Association of Molecular Pathology Annual Meeting*, Grapevine, TX, November, 2011
 17. Mies C, Goyal A, Bagg A, Frank DM, Barr F, **Aisner DL**, Roy DB, Jaffer S: Breast Implant Capsule-Associated Anaplastic Large Cell Lymphoma (BIC-ALCL); poster presentation at: *United States and Canadian Association of Pathology Annual Meeting*, Vancouver, BC, 2012
 18. Doebele RC, **Aisner DL**, Le AT, Berge EM, Pilling AB, Kutateladze TG, Weickhardt AJ, Franklin WA, Varella-Garcia M: Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC; platform presentation at: *American Society of Clinical Oncology Annual Meeting*, Chicago, IL, 2012
 19. Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Schulte N, Maxson D, **Aisner DL**, Franklin WA, Doebele RC, Varella-Garcia M: Native and rearranged ALK copy number and rearranged ALK cell count in NSCLC: Implications for ALK inhibitor therapy, platform presentation at: *American Society of Clinical Oncology Annual Meeting*, Chicago, IL, 2012
 20. **Aisner DL**, Rumery MD, Doebele RC, Kondo K, Linderman D, Thomas N, Varella-Garcia M, Franklin WA, Camidge DR: Specialized Specimen Handling for Molecular Testing: The 'Molecular Only' Approach Results in a High Success Rate for Molecular Testing in NSCLC, presented at: *ASTRO/ASCO/IASLC Multidisciplinary Symposium on Thoracic Oncology*, Chicago, IL, September, 2012
 21. Rumery MD, Camidge DR, Kondo K, Linderman D, Doebele RC, Thomas NJ, Varella-Garcia M, Ren Q, Franklin WA, **Aisner DL**: Specialized Specimen Handling for Molecular Testing of Solid Tumors: The 'Molecular Only' Approach Results in a High

- Success Rate for Molecular Testing, presented at: *Association for Molecular Pathology Annual Meeting*, Long Beach, CA, October, 2012
22. Weickhardt AW, Nguyen TT, Paskulin DD, Le AT, **Aisner DL**, Schulte N, Chionh F, Mariadason J, Tebbutt N, Doebele RC, Varella-Garcia M: *ALK* and *ROS1* Rearrangements Detected in Colorectal Cancer (CRC) by Fluorescence In Situ Hybridization, presented at: *American Society of Clinical Oncology Annual Meeting*, Chicago, IL, June, 2013
 23. Kris MG, Oxnard GR, Johnson BE, Berry LD, Chen H, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Franklin WA, **Aisner D**, Sequist LV, Khuri FR, Garon EB, Pao W, Rudin CM, Schiller JH, Haura EB, Minna JD, Bunn PA: Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC), poster presentation at: *American Society of Clinical Oncology Annual Meeting*, Chicago, IL, June 2013
 24. Varella-Garcia M, Xu LG, Mahale S, Berge E, Bennati C, Le AT, **Aisner DL**, Crino L, Bunn PA, Camidge DR, Doebele RC: *RET* rearrangements detected by FISH in Pan-Negative Lung Adenocarcinoma, presented at: *American Society of Clinical Oncology Annual Meeting*, Chicago, IL, June, 2013
 25. Doebele RC, Vaishnavi A, Capellitti M, Le AT, Kako S, Butaney M, Mahale S, **Aisner DL**, Haas J, Andrews SW, Lipson D, Stephens PJ, Varella-Garcia M, Janne PA, Miller VA: *NTRK1* Gene Fusions as a Novel Oncogene Target in Lung Cancer, presented at: *American Society of Clinical Oncology Annual Meeting*, Chicago, IL, June, 2013
 26. Siegele BJ, Shilo K, Carbone D, Edelman M, Zhao W, Ross P, Chao B, Franklin WA, **Aisner DL**: Case Series Report: *EGFR* Mutations in Small Cell Lung Carcinoma (SCLC), resident presentation at: *Association for Molecular Pathology Annual Meeting*, Phoenix, AZ, October, 2013
 27. **Aisner DL**, Bennati C, Mahale S, Xu LG, Le AT, Berge E, Chiari R, Crino L, Camidge DR, Bunn PA, Doebele RC, Varella-Garcia M: High proportion of gene fusion events detected by FISH in selected lung adenocarcinoma, poster presentation at: *Association for Molecular Pathology Annual Meeting*, Phoenix, AZ, October, 2013
 28. **Aisner DL**, Doebele RC, Hirsch FR, Hout DR, Le AT, Lu X, Schweitzer BL, Baron AE, Lawrence K, Boyle T, Morris SW, Camidge DR, Varella-Garcia M: Atypical Patterns of ALK Break-Apart FISH Analysis Indicate High Proportion of Positivity for ALK by Alternate Testing Methodologies, poster presentation at: *Association for Molecular Pathology Annual Meeting*, Phoenix, AZ, October, 2013
 29. Bennati C, Chiari R, Metro G, Iacono D, Varella-Garcia M, **Aisner D**, Minotti V, Meacci M, Paglialunga L, De Angelis V, Marcomingi L, Ludovini V, Tofanetti FR, Baglivo S, Bellezza G, Crino L: Clinical features and outcome in never-smoker (NS) non-small cell lung cancer (NSCLC) patient (pts): A single-institution observational analysis, e-poster for: *American Society of Clinical Oncology Annual Meeting*, June, 2014
 30. Doebele RC, Kako S, Le AT, daCosta Silva M, Vaishnavi A, Toschi L, Santoro A, Roncalli M, **Aisner DL** and Varella-Garcia M: Analysis of *NTRK1* gene fusion

- incidence in an unselected cohort of NSCLC patients, poster presentation at: *American Society of Clinical Oncology Annual Meeting*, June, 2014
31. Golan T, Eckhardt SG, Stossel C, Atias D, Wang G, Pitts TM, **Aisner D**, Weekes CD, Berger R, Tan AC: RNA-seq and KRAS mutational status in ascitic pancreatic cancer cells: Novel results and distinct subsets, e-poster for: *American Society of Clinical Oncology Annual Meeting*, June, 2014
 32. Varella-Garcia M, Becker AP, Sheren J, Neto CS, **Aisner DL**, Bidinotto L, Neder L, Jones C, Reis RM: Characterization of KIAA1549: BRAF fusion in young pilocytic astrocytoma patients through fluorescence in situ hybridization, poster presentation at: *American Society of Clinical Oncology Annual Meeting*, June, 2014
 33. **Aisner DL**, Sholl LM, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ: Multi-institutional multiplexed genetic analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium (LCMC I) experience, poster presentation at: *American Society of Clinical Oncology Annual Meeting*, June, 2014
 34. Ren Q, Haney J, Jones K, Gowan K, O'Neill PH, Bocsi G, Merrick D, Seager M, Siegele B, Franklin WA, **Aisner DL**: Validation of TruSight Tumor Panel Next Generation Sequencing Assay in Formalin-Fixed Paraffin Embedded Specimens, poster presentation at: *Association for Molecular Pathology Annual Meeting*, Washington, DC, November, 2014
 35. Li BT, Ross DS, Chaft JE, Hsu M, Kako S, **Aisner DL**, Kris MG, Varella-Garcia M, Arcila ME: Defining the spectrum of "overlap" of HER2 aberrations in lung cancer: Associations of HER2 protein overexpression, HER2 amplification and HER2 mutation, poster presentation at: *American Society of Clinical Oncology Annual Meeting*, Chicago, IL, May 2015
 36. Scott AJ, O'Neill BH, Ma WW, Cohen SJ, **Aisner D**, Menter AR, Tejani MA, Cho JK, Rubin P, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Philip PA, Boles J, Maguire RT, Wilhelm F, Maniar M, Gomes C, Messersmith WA: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer, poster presentation at: *American Society of Clinical Oncology Annual Meeting*, Chicago, IL, May 2015
 37. Vanderbilt CM, Fulchiero EC, Hoyer RJ, **Aisner DL**, Doebele RC: Two cases of NSCLC with EGFR Exon 20 insertions with major clinical response to Cetuximab-Containing Therapies, poster presentation at: *International Association for the Study of Lung Cancer World Conference on Lung Cancer*, Denver, CO, September, 2015
 38. Patil T, **Aisner DL**, Noonan SA, Bunn Jr PA, Berge EM, Purcell WT, Camidge R, Carr LL, Doebele RC: Malignant pleural effusions are predictive of peritoneal carcinomatosis in patients with advanced EGFR positive non-small cell lung cancer, Mini-Oral presentation at: *International Association for the Study of Lung Cancer World Conference on Lung Cancer*, Denver, CO, September, 2015
 39. Sheren J, **Aisner DL**, Merrick DT, Berge EM, Chesnut P, Doebele RC, Camidge R, Varella-Garcia M: Clinicopathologic profiles of ROS1 positive patients screened by

- FISH, Mini-Oral presentation at: *International Association for the Study of Lung Cancer World Conference on Lung Cancer*, Denver, CO, September, 2015
40. Rivard CJ, Boyle TA, Ren Q, Kowalewski AA, Hozak RR, Mi G, Kurljac-Letunic A, Melemed S, Kurek R, **Aisner DL**, Hirsch FR: Mutation prevalence for oncogenic drivers in lung adenocarcinoma, Mini-Oral presentation at: *International Association for the Study of Lung Cancer World Conference on Lung Cancer*, Denver, CO, September, 2015
 41. Vaishnavi A, Keysar SB, Le AT, **Aisner DL**, Heasley L, Jimeno A, Doebele RC: Adaptive survival signaling in oncogenic fusion kinase addicted NSCLC, Oral presentation at: *International Association for the Study of Lung Cancer World Conference on Lung Cancer*, Denver, CO, September, 2015
 42. Estrada-Bernal A, Le AT, Zhou H, Noonan SA, **Aisner DL**, Camidge R, Doebele RC: A novel cell line model of EGFR exon 20 insertion mutations, Mini-Oral presentation at: *International Association for the Study of Lung Cancer World Conference on Lung Cancer*, Denver, CO, September, 2015
 43. Varella-Garcia M, Kako SL, Nguyen CM, Saichaemchan S, Ariyawutyakorn W, De S, Keysar SB, Jimeno A, Roncalli M, Santoro A, Toschi L, Le AT, **Aisner DL**, Doebele RC : FISHing TRK activation by gene rearrangements in non-small cell lung cancer, Oral presentation at: *International Association for the Study of Lung Cancer World Conference on Lung Cancer*, Denver, CO, September, 2015
 44. Dziadziuszko R, Le AT, **Aisner DL**, Wrona A, Doebele RC: ROS1 resistance to crizotinib is mediated by an activating mutation in C-KIT, Mini-Oral presentation at: *International Association for the Study of Lung Cancer World Conference on Lung Cancer*, Denver, CO, September, 2015
 45. Mann P, Sheren J, Merrick DT, Franklin WA, Varella-Garcia M, Jones KL, **Aisner DL**: Evaluation of a next-generation sequencing copy number variation algorithm as an initial screen for the detection of target gene amplification in a clinical laboratory setting, poster presentation at: *Association for Molecular Pathology Annual Meeting*, Austin, Tx, November, 2015
 46. Vanderbilt CM, O'Rourke R, O'Neill P, Gowan K, Haney J, Davies KD, Bocsi G, Jones KL, Merrick DT, **Aisner DL**: Updating a bioinformatics process for analysis of next generation sequencing: An approach to pipeline revalidation, poster presentation at: *Association for Molecular Pathology Annual Meeting*, Austin, Tx, November, 2015
 47. Farooqi MS, Davies KD, Gruidl M, Hill CE, Hirschorn JW, Jones H, Jones KL, Magliocco A, O'Rourke R, Patel NM, Qin D, Ramos E, Rossi MR, Schneider TM, Smith GH, Park JY, **Aisner DL**: Multi-institutional FASTQ proficiency testing reveals high concordance in reporting clinically significant single-nucleotide variants but discrepancies in reporting insertions/deletions, poster presentation at: *Association for Molecular Pathology Annual Meeting*, Austin, Tx, November, 2015 **MS Farooqi was winner of the Young Investigator Award
 48. Bingham VR, Ren Q, Merrick DT, **Aisner DL**, Bocsi G: Implementation of an individualized quality control plan (IQCP) in a CLIA regulated molecular laboratory,

- poster presentation at: *Association for Molecular Pathology Annual Meeting*, Austin, Tx, November, 2015
49. McCoach CE, Le AT, **Aisner D**, Gowan K, Jones KL, Merrick D, Bunn PA, Purcell WT, Varella-Garcia M, Camidge DR, Doebele RC: Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer, poster presentation at: *American Society of Clinical Oncology Annual Meeting*, June, 2016
 50. **Aisner D**, Sholl LM, Berry LD, Haura EB, Ramalingam SS, Glisson BS, Socinski, Saiama MA, Waqar N, Garon EB, Cetnar JP, Politi KA, Schiller J, Rossi MR, Chen H, John D. Minna, Ignacio Ivan Wistuba, Bruce E. Johnson, Mark G. Kris, Paul A. Bunn, Kwiatkowski DJ: Expanded Genomic Testing in Lung Adenocarcinoma Expands the Survival Benefit, poster presentation (featured) at: *American Society of Clinical Oncology Annual Meeting*, June, 2016
 51. Davies KD, Mann P, Le AT, Haney J, Berlin AM, Reckase E, Banos MS, Varella-Garcia M, Doebele RC, Camidge DR, **Aisner DL**: Detection of a complex *EML4-ALK* fusion transcript via anchored multiplex PCR and *de novo* assembly of next-generation sequencing reads, poster presentation at: *Association for Molecular Pathology Annual Meeting*, November, 2016
 52. Mann P, Davies KD, **Aisner DL**: ALK expression in a non-small cell lung cancer not associated with ALK rearrangement by FISH or by targeted NGS-based fusion assay, early bird oral presentation at: *Association for Molecular Pathology Annual Meeting*, November, 2016
 53. Schneider TM, Rouhi O, Wang J, Davies KD, Gruidl M, Woolworth-Hirschhorn J, Kadri Sabah, Box AH, Clay MR, Farooqi MS, Hill CE, Jones H, Jones KL, Magliocco A, Mitui M, O'Neill PH, O'Rourke R, Patel NM, Qin D, Ramos E, Rossi MR, Smith GH, Segal JP, Park JY, **Aisner DL** and Zhang L: Proficiency Testing for Next-Generation Sequencing: Multi-Institutional FASTQ File, poster presentation at: *Association for Molecular Pathology Annual Meeting*, November, 2016
 54. Owen DH, Bunn PA, Johnson BE, Kwiatkowski DJ, Kris MG, Wistuba II, Gandhi M, Phan S, Shames DS, Schulze K, Yu W, **Aisner D**, Chaft JE, Garon EB, Lee JM, Minna JD, Rusch VW, Reckamp KL, Wozniak AJ, Carbone DP, LCMC3 Investigators A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC), poster presentation at: *American Society of Clinical Oncology Annual Meeting*, June, 2017
 55. McCoach CE, Merrick D, **Aisner DL**, Bunn PA, Camidge DR, Gao D, Kondo K, Doebele RC: Early rebiopsy to identify mechanisms and biomarkers of tumor cell survival following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy, poster presentation at: *American Society of Clinical Oncology Annual Meeting*, June, 2017
 56. Iyer P, Wong K, Lieu CH, Henry J, Davis SL, Goodman KA, Davies K, **Aisner D**, Messersmith WA, Leong S: Clinical and molecular characteristics of younger versus older patients with colorectal cancer. Poster presentation at: *American Society of Clinical Oncology*, June, 2018

57. Patil T, Mushtaq RR, Marsh S, Azelby C, Pujara M, **Aisner D**, Purcell WT, Schenk EL, Bunn PA, Pacheco JM, Camidge DR, Doebele RC: The clinicopathologic characteristics and optimal treatment strategies for non-sensitizing EGFR (ns-EGFR) and HER2 activating mutations in NSCLC remain unclear. Poster presentation at: *American Society of Clinical Oncology Annual Meeting*, June, 2019
58. Patil T, Dimou A, Pacheco J, Smith D, **Aisner D**, Merrick D, Rusthoven C, Kavanaugh B, Miller R, Schenk E, Camidge DR, Bunn P, Doebele R: Osimertinib Acquired Resistance Mechanisms and Post-Progression Outcomes in Stage IV EGFR Positive Non-Small Cell Lung Cancer, Poster Presentation at: *World Conference on Lung Cancer*, Barcelona, Spain 2019
59. Le A, Tyler L, Davies K, Kondo K, Pacheco J, Merrick D, **Aisner D**, Camidge DR, Doebele R: Unveiling Hidden MET-Mediated Primary Alectinib Resistance in ALK-Positive Non-Small Cell Lung Cancer, Poster Presentation at: *World Conference on Lung Cancer*, Barcelona, Spain 2019
60. Rotow J, Urisman A, McCoach C, Jahan T, Bivona T, Jones K, Gupta A, Do H, Riess J, **Aisner D**, Doebele R, Jablons D, Kratz J, Blakely C: A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer, Poster Presentation at: *World Conference on Lung Cancer*, Barcelona, Spain 2019
61. Dimou A, Patil T, Jeffers A, Guimares-Young A, Davies K, Nance T, He Y, Jaimovich A, Raymond V, Talasaz A, Schenk E, Pacheco J, **Aisner D**, Merrick D, Scott C, Mitchell J, Weyant M, Meguid R, Purcell WT, Bunn P, Camidge DR, Ng T, McCoach C, Doebele R: Detection of CTDNA and Correlation with Tumor Mutation Testing in Early Stage NSCLC, Poster Presentation at: *World Conference on Lung Cancer*, Barcelona, Spain 2019
62. Bauml JM, Mick R, McCoach C, Weiss J, Marrone K, Nieva J, Villaruz L, Levy B, Moreno RN, Murkherji R, Sun F, Schwartzman W, Shaverdashvili K, Wang X, Shah MH, Woodley JT, Miller NG, Succe CL, Ullah T, Lovely CM, Doebele R, Iams WT, Horn L, Dowell J, Liu G, Leighl N, Patil T, Liu SV, Velcheti V, **Aisner D**, Camidge DR: Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study. Featured poster presentation at: *World Conference on Lung Cancer*, 2020 (held virtually in January, 2021)
63. Blakely CM, Urisman A, Kerr DL, Wu W, Bacaltos B, Rotow J, Gubens M, Bivona T, Jones K, Riess J, Aisner DL, Doebele R, Patil T, Schenk E, Kratz J, and Jablons D: Phase II trial of neoadjuvant osimertinib for surgically resectable, EGFR-mutant non-small cell lung cancer, presented at World Lung Conference on Lung Cancer, 2021 (virtual)